Tools currently available in clinical practice are not able to quantitatively measure changes in multiple sclerosis (MS) disease activity. Ferhan Qureshi, BS, Vice President, Octave Bioscience, Menlo Park, CA, discusses the multivariate proteomic multiple sclerosis disease activity (MSDA) test, which measures the concentration of 18 proteins to determine four disease pathways (immunomodulation, neuroinflammation, myelin biology, and neuroaxonal integrity) and an overall disease activity score. The MSDA test is part of a comprehensive care solution that includes two other tools: enhanced MRI insights and clinical insights programs. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.
Ferhan Qureshi is an employee at Octave Bioscience